StockNews.com began coverage on shares of The Dixie Group (NASDAQ:DXYN – Free Report) in a research note released on Saturday morning. The firm issued a hold rating on the textile maker’s stock.
The Dixie Group Stock Down 0.7 %
Shares of The Dixie Group stock opened at $0.71 on Friday. The Dixie Group has a one year low of $0.45 and a one year high of $1.05. The company has a market cap of $10.92 million, a P/E ratio of -3.55 and a beta of 2.64. The company has a debt-to-equity ratio of 3.60, a quick ratio of 0.87 and a current ratio of 2.54. The firm has a fifty day moving average of $0.77 and a two-hundred day moving average of $0.75.
The Dixie Group (NASDAQ:DXYN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The textile maker reported $0.04 earnings per share for the quarter. The company had revenue of $70.51 million for the quarter. The Dixie Group had a negative return on equity of 7.65% and a negative net margin of 0.99%.
Institutional Investors Weigh In On The Dixie Group
The Dixie Group Company Profile
The Dixie Group, Inc manufactures, markets, and sells floorcovering products to residential customers in North America and internationally. The company offers residential carpets, custom rugs, and engineered wood products under the Fabrica brand for interior decorators and designers, selected retailers and furniture stores, luxury home builders, and manufacturers of luxury motor coaches and yachts; and specialty carpets and rugs for the high-end residential marketplace, as well as luxury vinyl flooring products and broadloom carpet products under the Masland Residential brand name through the interior design community and specialty floorcovering retailers.
See Also
- Five stocks we like better than The Dixie Group
- The 3 Best Blue-Chip Stocks to Buy Now
- Intel: Is Now the Time to Be Brave?Â
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Investing in Travel Stocks Benefits
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for The Dixie Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Dixie Group and related companies with MarketBeat.com's FREE daily email newsletter.